Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer
Journal Title: Journal of Oncobiomarkers - Year 2015, Vol 2, Issue 1
Abstract
mTOR is a serine/threonine kinase and plays a critical role in mammalian cell growth, survival, and metabolism. mTOR is present in two cellular complexes: mTORC1 and mTORC2. Dysregulation of the mTOR pathway has been related to tumorigenesis, poor prognosis and/or chemotherapy resistance in a variety of malignancies. Inhibition of mTORC1 by Rapamycin and its analogs has been explored to treat a number of tumors. However, the effectiveness of atient response is limited and not all patients respond. Second generation of mTOR inhibitors have recently been developed to target mTOR kinase activity and to suppress both mTORC1 and mTORC2. Dual mTORC1/mTORC2 inhibitors generally are more efficacious in preclinical studies and clinical trials. We and others have recently found that dual mTORC1/mTORC2 inhibitors sensitize T-cell acute lymphocytic leukemia and rhabdomyosarcoma cells to DNA damaging agents by suppression of expression of FANCD2 of the Fanconi anemia pathway, an important DNA repair mechanism that is associated with drug resistance of multiple types of cancer. This review will highlight mTOR and the Fanconi anemia pathway in cancer, with a particular attention to our newly discovered connection between mTOR and the Fanconi anemia pathway.
Authors and Affiliations
Fukun Guo
Keywords
Related Articles
- EP ID EP240038
- DOI 10.13188/2325-2340.1000008
- Views 121
- Downloads 0
Extracellular Domain Mutation of ErbB2 Status in Japanese Lung Cancer Patients
Purpose: The erbB pathway involves a family of tyrosine kinases and has contributed to resistance or sensitivity for chemotherapy in many tumor types. Somatic mutations of the erbB family receptor gene at kinase domain w...
Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer
mTOR is a serine/threonine kinase and plays a critical role in mammalian cell growth, survival, and metabolism. mTOR is present in two cellular complexes: mTORC1 and mTORC2. Dysregulation of the mTOR pathway has been rel...
Chemokine Receptors as Biomarkers in Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is reported to be the 6th most common solid tumor diagnosed in the world [1]. Around 95% head and neck cancers are squamous cell carcinomas originating in the upper aerod...
IRF4 as an Oncogenic Biomarker for Hematological Malignancies
The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is crucial for lymphocyte development. Importantly, IRF4 has potent oncogenic and transforming properties, and its intimate interac...
KSHV Down-regulates Tropoelastin in Both an in-vitro and in-vivo Kaposi’s Sarcoma Model
Kaposi’s sarcoma (KS), a common cancer in individuals with HIV/ AIDS, lacks a curative therapy. Few studies have examined changes in extracellular matrix (ECM) protein profiles in the development of KS. Here we used an i...